



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 1				Complete if Known	
		Application Number		10/573,131	
		Filing Date		April 18, 2006	
		First Named Inventor		Darrel W. Stafford	
		Group Art Unit		1634	
		Examiner Name		J. Sitton	
Attorney Docket Number		5470-401			

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials *	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			
							No

OTHER NON PATENT DOCUMENTS					T
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	1.	ICOS "Factor IX Cell Culture Process" Version 2.0 (12 pages) (2006)			
	2.	Bogousslavsky et al. "Anticoagulant-induced intracerebral bleeding in brain ischemia" <i>Acta Neurol Scand.</i> 71:464-471 (1985)			
	3.	Chen et al. "Calcium Phosphate-Mediated Gene Transfer: A Highly Efficient Transfection System for Stably Transforming Cells with Plasmid DNA" <i>BioTechniques</i> 6(7):632-638 (1988)			
	4.	Ekelund et al. "Combined Deficiency of Coagulation Factors II, VII, IX, and X: A Case of Probable Congenital Origin" <i>Pediatric Hematology and Oncology</i> 3:187-193 (1986)			
	5.	Furuya et al. "Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy" <i>Pharmacogenetics</i> 5:389-392 (1995)			
	6.	Gan et al. "Racial Background Is a Determinant Factor in the Maintenance Dosage of Warfarin" <i>International Journal of Hematology</i> 78:84-86 (2003)			
	7.	Gullov et al. "Bleeding Complications to Long-Term Oral Anticoagulant Therapy" <i>Journal of Thrombosis and Thrombolysis</i> 1:17-25 (1994)			
	8.	Nasu et al. "Genetic analysis of CYP2C9 polymorphism in a Japanese population" <i>Pharmacogenetics</i> 7:405-409 (1997)			
	9.	Prentice "Acquired Coagulation Disorders" <i>Clin. Haematol.</i> 14(2):413-442 (1985)			
	10.	Suttie "The Biochemical Basis of Warfarin Therapy" <i>Adv. Exp. Med. Bio.</i> 214:3-16 (1987)			
	11.	Vermeer et al. "Vitamin K-Dependent Carboxylase" <i>Haematologia</i> 18(2):71-97 (1985)			
	12.	Vincente et al. "Congenital Deficiency of Vitamin K-Dependent Coagulation Factors and Protein C" <i>Thromb Haemostas (Stuttgart)</i> 51(3):343-346 (1984)			
	13.	Wallace et al. "A major gene controlling warfarin-resistance in the house mouse" <i>J. Hyg., Camb.</i> 76:173-181 (1976)			
	14.	Yu et al. "Factors determining the maintenance dose of warfarin in Chinese patients" <i>Q J Med</i> 89:127-135 (1996)			
	15.	Zwaal et al. "Lipid-protein interactions in blood coagulation" <i>Biochimica et Biophysica Acta</i> 1376:433-453 (1998)			

Examiner Signature	/Jehanne Sitton/	Date Considered	06/19/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.